Therapeutic Strategies for Immune Transformation in Parkinson’s Disease

por Saleh, Maamoon, Markovic, Milica, Olson, Katherine E., Gendelman, Howard E., Mosley, R. Lee
Publicado 2022

Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders

por Anderson, Kristi M, Olson, Katherine E, Estes, Katherine A, Flanagan, Ken, Gendelman, Howard E, Mosley, R Lee
Publicado 2014

Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders

por Machhi, Jatin, Kevadiya, Bhavesh D., Muhammad, Ijaz Khan, Herskovitz, Jonathan, Olson, Katherine E., Mosley, R. Lee, Gendelman, Howard E.
Publicado 2020

Immunotherapy for Parkinson’s disease

por Schwab, Aaron D., Thurston, Mackenzie J., Machhi, Jatin, Olson, Katherine E., Namminga, Krista L., Gendelman, Howard E., Mosley, R. Lee
Publicado 2020

Interleukin-2 expands neuroprotective regulatory T cells in Parkinson’s disease

por Markovic, Milica, Yeapuri, Pravin, Namminga, Krista L., Lu, Yaman, Saleh, Maamoon, Olson, Katherine E., Gendelman, Howard E., Mosley, R. Lee
Publicado 2022

Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease

por Abdelmoaty, Mai M., Machhi, Jatin, Yeapuri, Pravin, Shahjin, Farah, Kumar, Vikas, Olson, Katherine E., Mosley, R. Lee, Gendelman, Howard E.
Publicado 2022

An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers

por Olson, Katherine E., Abdelmoaty, Mai M., Namminga, Krista L., Lu, Yaman, Obaro, Helen, Santamaria, Pamela, Mosley, R. Lee, Gendelman, Howard E.
Publicado 2023

A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease

por Mosley, R. Lee, Lu, Yaman, Olson, Katherine E., Machhi, Jatin, Yan, Wenhui, Namminga, Krista L., Smith, Jenell R., Shandler, Scott J., Gendelman, Howard E.
Publicado 2019

Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease

por Olson, Katherine E., Namminga, Krista L., Lu, Yaman, Schwab, Aaron D., Thurston, Mackenzie J., Abdelmoaty, Mai M., Kumar, Vikas, Wojtkiewicz, Melinda, Obaro, Helen, Santamaria, Pamela, Mosley, R. Lee, Gendelman, Howard E.
Publicado 2021

Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions

por Abdelmoaty, Mai M., Yeapuri, Pravin, Machhi, Jatin, Olson, Katherine E., Shahjin, Farah, Kumar, Vikas, Zhou, You, Liang, Jingjing, Pandey, Kabita, Acharya, Arpan, Byrareddy, Siddappa N., Mosley, R. Lee, Gendelman, Howard E.
Publicado 2021

Humanized Mice for Infectious and Neurodegenerative disorders

por Dash, Prasanta K., Gorantla, Santhi, Poluektova, Larisa, Hasan, Mahmudul, Waight, Emiko, Zhang, Chen, Markovic, Milica, Edagwa, Benson, Machhi, Jatin, Olson, Katherine E., Wang, Xinglong, Mosley, R. Lee, Kevadiya, Bhavesh, Gendelman, Howard E.
Publicado 2021

CD4+ effector T cells accelerate Alzheimer’s disease in mice

por Machhi, Jatin, Yeapuri, Pravin, Lu, Yaman, Foster, Emma, Chikhale, Rupesh, Herskovitz, Jonathan, Namminga, Krista L., Olson, Katherine E., Abdelmoaty, Mai Mohamed, Gao, Ju, Quadros, Rolen M., Kiyota, Tomomi, Jingjing, Liang, Kevadiya, Bhavesh D., Wang, Xinglong, Liu, Yutong, Poluektova, Larisa Y., Gurumurthy, Channabasavaiah B., Mosley, R. Lee, Gendelman, Howard E.
Publicado 2021

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial

por Gendelman, Howard E., Zhang, Yuning, Santamaria, Pamela, Olson, Katherine E., Schutt, Charles R., Bhatti, Danish, Shetty, Bhagya Laxmi Dyavar, Lu, Yaman, Estes, Katherine A., Standaert, David G., Heinrichs-Graham, Elizabeth, Larson, LuAnn, Meza, Jane L., Follett, Matthew, Forsberg, Erica, Siuzdak, Gary, Wilson, Tony W., Peterson, Carolyn, Mosley, R. Lee
Publicado 2017